The decreased tumor size and enhanced tumor rejection in DGKζ - deficient mice indirectly suggests that enhanced Erk signaling may be superior to enhanced NF - κΒ activation in facilitating T cell activity against tumor, especially because DKO mice did not exhibit improved
tumor control relative to DGKζ − / − mice.
Not exact matches
Therapy of doxorubicin resistant MX - 1
tumors with MIA - 602 or combination led to significant (P < 0.05) reduction in MDR1 and NANOG gene expression
relative to
controls.
In - vivo treatment of HCC1806
tumors with MIA - 602, doxorubicin, or combination resulted in significant (P < 0.01) suppression of MDR1 and NANOG gene expression
relative to
controls.